Literature DB >> 2919636

Idiopathic pulmonary fibrosis: cellular and molecular pathogenesis.

J C Weissler1.   

Abstract

Diffuse involvement of the pulmonary interstitium with abnormal fibrous tissue is a process that occurs in many settings. There are many possible etiologies for pulmonary fibrosis, but in the majority of individuals, a clear cause cannot be determined and a diagnosis of idiopathic pulmonary fibrosis (IPF) results. Despite limited knowledge concerning the etiology, recent advances in biomedical technology offer great promise for increasing our understanding of IPF. This review will focus on current concepts of the pathogenesis and therapy of IPF.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2919636     DOI: 10.1097/00000441-198902000-00005

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  16 in total

1.  Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters.

Authors:  Q Wang; Y Wang; D M Hyde; P J Gotwals; V E Koteliansky; S T Ryan; S N Giri
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 2.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

3.  Effects of erdosteine on bleomycin-induced lung fibrosis in rats.

Authors:  Haşim Boyaci; Hale Maral; Gupse Turan; Ilknur Başyiğit; Meltem O Dillioğlugil; Füsun Yildiz; Melih Tugay; Ayşe Pala; Cengiz Erçin
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

4.  National Scientific Medical Meeting. The Royal College of Physicians of Ireland. Dublin, 8-9 April 1994. Abstracts.

Authors: 
Journal:  Ir J Med Sci       Date:  1994-04       Impact factor: 1.568

5.  Rising mortality from cryptogenic fibrosing alveolitis.

Authors:  I Johnston; J Britton; W Kinnear; R Logan
Journal:  BMJ       Date:  1990-11-03

6.  Similar frequency of autoantibodies against pneumocytes type II and Clara cells in patients with interstitial lung diseases and healthy persons.

Authors:  R Erlinger; G Rauh; J Behr; U Schumacher; U Welsch; N Zöllner
Journal:  Klin Wochenschr       Date:  1991-05-03

7.  Alveolar macrophages from bronchoalveolar lavage of patients with pulmonary histiocytosis X: determination of phenotypic and functional changes.

Authors:  M Uebelhoer; B Bewig; K Sternberg; K Rabe; D Nowak; H Magnussen; J Barth
Journal:  Lung       Date:  1995       Impact factor: 2.584

8.  Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance.

Authors:  Norihiro Kikuchi; Yukio Ishii; Yuko Morishima; Yuichi Yageta; Norihiro Haraguchi; Ken Itoh; Masayuki Yamamoto; Nobuyuki Hizawa
Journal:  Respir Res       Date:  2010-03-18

Review 9.  Alteration of Aging-Dependent MicroRNAs in Idiopathic Pulmonary Fibrosis.

Authors:  Richard Seonghun Nho
Journal:  Drug Dev Res       Date:  2015-08-25       Impact factor: 4.360

10.  Interleukin-13 fusion cytotoxin arrests Schistosoma mansoni egg-induced pulmonary granuloma formation in mice.

Authors:  Claudia Jakubzick; Steven L Kunkel; Bharat H Joshi; Raj K Puri; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.